STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company was founded in 1982 and is based in Monrovia, California.
STAA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for STAA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Staar Surgical Co ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Staar Surgical Co, consider:
Staar Surgical Co's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -32.59. This coverage rate is greater than that of just 4.14% of stocks we're observing for the purpose of forecasting via discounted cash flows.
As a business, Staar Surgical Co experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
CTLT, AGHC, ALC, AMRN, and ATRS can be thought of as valuation peers to STAA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
LOS ANGELES, Sept. 15, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming October 19, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased STAAR Surgical Company ("STAAR" or the "Company")…
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the common stock of Staar Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) between February 26, 2020, and August 10, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Central District of Ca
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its U.S. FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens.” Primary study analysis will be conducted when 300 primary eyes complete 6
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of STAAR Surgical Company (NASDAQ: STAA) between February 26, 2020 and August 10, 2020, inclusive (the “Class Period”) of the important October 19, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for STAAR investors under the federal securities laws. To join the STAAR class action, go to http://www.rosenlegal.com/cases-register-1924